MedTrace Logo

Cambridge Liquid Biopsy and Tumour Profiling Study for Patients on Experimental Therapeutics Trials

NCT02994511 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2019-07-22

No results posted yet for this study

Summary

This study will explore the potential of the circulating tumour DNA (ctDNA) as predictive factor of response/resistance to anticancer treatment. The project will involve the collection and study of the archived tumour tissue where available (mandatory), serial blood samples (mandatory) and fresh tumour biopsies (optional) from patients taking part in an early phase clinical trial.

Conditions

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • CCTU- Cancer Theme

    lead OTHER

Principal Investigators

  • Richard Baird · Cambridge University Hospitals NHS Foundation Trust

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-08
Primary Completion
2020-03-30
Completion
2020-03-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02994511 on ClinicalTrials.gov